by Chris Dokomajilar | Apr 19, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology The biotech industry is facing a critical moment as it enters 2023. The previous year was challenging for the sector, as initial public offerings decreased, and a biotech stock index declined by...
by Chris Dokomajilar | Apr 3, 2023 | Analysis, Funding, M&A, Partnership Deals
Deal Flow in 2022 Returned to pre-2019 Levels Lower Deal Dollars Across All Healthcare and Life Sciences Licensing Terms are Shifting to More in Milestones Large Cap Biopharma In-Licensing and Buying in 2022 Big...
by Chris Dokomajilar | Mar 16, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D Partnerships, M&A, Ventures, & IPOs in T.A. – Cancer The pharmaceutical industry continues to place significant emphasis on cancer treatment. A report by the International Agency for Cancer Research suggests that the number of deaths resulting from...
by Chris Dokomajilar | Mar 11, 2023 | Analysis, M&A
M&A – Medtech Medical technology, or MedTech, is a multidisciplinary field that combines technology and medical interventions. It encompasses various technologies, devices, services, products, and solutions that employ medical technology to improve patient care...
by Chris Dokomajilar | Mar 10, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D PARTNERSHIPS – MEDTECH As we enter the first quarter of 2023, there is a persistent rise in R&D spending despite the mounting pressure to cut costs, reduce budgets and enhance profit margins. The life sciences sector anticipated an R&D expenditure of...
by Ani Harutyunyan | Mar 9, 2023 | Analysis, Funding, M&A, Partnership Deals
Biopharma Reverse Mergers And SPACs– What Happened Since 2020 The biopharmaceutical industry has seen a significant uptick in using reverse mergers and Special Purpose Acquisition Companies (SPACs) to go public since 2020. This trend has been partly driven by the...
